Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9793212 | 1.00 | ALOX15 (0.41) | ALOX15 | |
| SCHEMBL22107929 | 0.89 | ALOX15 (0.42) | ALOX15 | |
| SCHEMBL13542776 | 0.80 | ALOX15 (0.44) | ALOX15 | |
| SCHEMBL17705970 | 0.78 | ALOX15 (0.40) | ALOX15 | |
| SCHEMBL14212100 | 0.75 | ALOX15 (0.42) | ALOX15 | |
| SCHEMBL14181275 | 0.75 | ALOX15 (0.42) | ALOX15 | |
| SCHEMBL13468648 | 0.75 | ALOX15 (0.42) | ALOX15 | |
| SCHEMBL22984177 | 0.74 | ALOX15 (0.55) | ALOX15 | |
| SCHEMBL10451761 | 0.74 | ALOX15 (0.55) | ALOX15 | |
| SCHEMBL22140861 | 0.74 | ALOX15 (0.55) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222458-B2 | Process or synthesis of (3S)- and (3R)-3-hydroxy-beta-ionone, and their transformation to zeaxanthin and beta-cryptoxanthin | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222458-B2 | Process or synthesis of (3S)- and (3R)-3-hydroxy-beta-ionone, and their transformation to zeaxanthin and beta-cryptoxanthin | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090311761-A1 | Process for Synthesis of (3S)- and (3R)-3-Hydroxy-Beta-Ionone, and Their Transformation to Zeaxanthin and Beta-Cryptoxanthin | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2009-12-17 | — | — | US | disclosed |
| US-20090311761-A1 | Process for Synthesis of (3S)- and (3R)-3-Hydroxy-Beta-Ionone, and Their Transformation to Zeaxanthin and Beta-Cryptoxanthin | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2009-12-17 | — | — | US | disclosed |
| US-4983723-A | Cycloalkane derivatives | GREEN CROSS CORPORATION (JP) | 1991-01-08 | — | — | US | disclosed |
| EP-0270124-A2 | Cycloalkane derivatives and anti-peptic ulcer compositions containing same | THE GREEN CROSS CORPORATION (JP) | 1988-06-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311761-A1 | Process for Synthesis of (3S)- and (3R)-3-Hydroxy-Beta-Ionone, and Their Transformation to Zeaxanthin and Beta-Cryptoxanthin | GRK1, HSD3B1, ALDH1A2 | ALOX15 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.